Targeting virulence mechanisms for the prevention and therapy of arenaviral hemorrhagic fever

Antiviral Research

Volumn 97, Issue 2, 2013, Pages 81-92

  McLay, Lisa ^a   Ansari, Aftab ^a   Liang, Yuying ^b   Ly, Hinh ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antiviral therapy; Arenavirus; Lassa virus; Viral hemorrhagic fever; Virulence mechanisms

Indexed keywords

BETA INTERFERON; DIHYDROLIPOAMIDE DEHYDROGENASE; FATTY ACID BINDING PROTEIN; INITIATION FACTOR 4E; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; KEXIN; SUBTILISIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL ACTIVITY; ARENAVIRAL HEMORRHAGIC FEVER; ARENAVIRUS INFECTION; BINDING AFFINITY; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; DISEASE COURSE; GENE EXPRESSION; GENE FREQUENCY; GENE REPLICATION; GENETIC TRANSCRIPTION; HEMORRHAGIC FEVER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INNATE IMMUNITY; LIFE CYCLE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MESSENGER RNA SYNTHESIS; MYRISTYLATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; RECEPTOR BINDING; REVERSE GENETICS; REVIEW; RNA DEGRADATION; SURVIVAL RATE; UNTRANSLATED REGION; VIRUS ENTRY; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS VIRULENCE;

ARENAVIRUS; HEMORRHAGIC FEVER, AMERICAN; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRAL PROTEINS; VIRULENCE FACTORS;

ANIMALIA; ARENAVIRUS; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; SABIA VIRUS;

EID: 84871555299     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.12.003     Document Type: Review

References (146)

1. Abraham J., Kwong J.A., Albariño C.G., Lu J.G., Radoshitzky S.R., Salazar-Bravo J., Farzan M., Spiropoulou C.F., Choe H. Host-species transferrin receptor 1 orthologs are cellular receptors for nonpathogenic New World Clade B arenaviruses. PLoS Pathog. 2009, 5:e1000358.
2. Aguilar P.V., Camargo W., Vargas J., Guevara C., Roca Y., Felices V., Laguna-Torres V.A., Tesh R., Ksiazek T.G., Kochel T.J. Reemergence of Bolivian hemorrhagic fever, 2007-2008. Emerging Infect. Dis. 2009, 15:1526-1528.
3. Al-Zein N., Boyce T.G., Correa A.G., Rodriguez V. Meningitis caused by lymphocytic choriomeningitis virus in a patient with leukemia. J. Pediatr. Hematol. Oncol. 2008, 30:781-784. 10.1097/MPH.0b013e318182e72b.
4. Albariño C.G., Bird B.H., Chakrabarti A.K., Dodd K.A., Erickson B.R., Nichol S.T. Efficient rescue of recombinant Lassa virus reveals the influence of s segment noncoding regions on virus replication and virulence. J. Virol. 2011, 85:4020-4024.
5. Albariño C.G., Bird B.H., Chakrabarti A.K., Dodd K.A., Flint M., Bergeron é., White D.M., Nichol S.T. The major determinant of attenuation in mice of the Candid1 vaccine for argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain. J. Virol. 2011, 85:10404-10408.
6. Althage A., Odermatt B., Moskophidis D., Kündig T., Hengartner U.H.-R.H., Zinkernagel R.M. Immunosuppression by lymphocytic choriomeningitis virus infection: competent effector T and B cells but impaired antigen presentation. Eur. J. Immunol. 1992, 22:1803-1812.
7. Alvarez C.P., Lasala F., Carrillo J., Muñiz O., Corbí A.L., Delgado R. C-Type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 2002, 76:6841-6844.
8. Ambrosio A., Saavedra M., Mariani M., Gamboa G., Maiza A. Argentine hemorrhagic fever vaccines. Hum. Vaccin. 2011, 7:694-700.
9. Andersen K.G., Shylakhter I., Tabrizi S., Grossman S.R., Happi C.T., Sabeti P.C. Genome-wide scans provide evidence for positive selection of genes implicated in Lassa fever. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012, 367:868-877.
10. Andrews N.C., Fleming M.D., Levy J.E. Molecular insights into mechanisms of iron transport. Curr. Opin. Hematol. 1999, 6:61.
11. Aronson J., Herzog N., Jerrells T. Pathological and virological features of arenavirus disease in guinea pigs. Comparison of two Pichinde virus strains. Am. J. Pathol. 1994, 145:228-235.
12. Artuso M.C., Ellenberg P.C., Scolaro L.A., Damonte E.B., García C.C. Inhibition of Junín virus replication by small interfering RNAs. Antiviral Res. 2009, 84:31-37.
13. Baize S., Kaplon J., Faure C., Pannetier D., Georges-Courbot M.-C., Deubel V. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J. Immunol. 2004, 172:2861-2869.
14. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
15. Bedossa P., Ferlicot S., Paradis V., Dargere D., Bonvoust F., Vidaud M. Dystroglycan expression in hepatic stellate cells: role in liver fibrosis. Lab. Invest. 2002, 82:1053-1061.
16. Bergthaler A., Flatz L., Hegazy A.N., Johnson S., Horvath E., Löhning M., Pinschewer D.D. Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression. Proc. Natl. Acad. Sci. 2010, 107:21641-21646.
17. Beyer W.R., Pöpplau D., Garten W., von Laer D., Lenz O. Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J. Virol. 2003, 77:2866-2872.
18. 8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009, 10:29-37.
19. Bonhomme C.J., Capul A.A., Lauron E.J., Bederka L.H., Knopp K.A., Buchmeier M.J. Glycosylation modulates arenavirus glycoprotein expression and function. Virology 2011, 409:223-233.
20. Bonthius D.J. Lymphocytic choriomeningitis virus: an underrecognized cause of neurologic disease in the fetus, child, and adult. Semin. Pediatr. Neurol. 2012, 19:89-95.
21. Briese T., Paweska J.T., McMullan L.K., Hutchison S.K., Street C., Palacios G., Khristova M.L., Weyer J., Swanepoel R., Egholm M., Nichol S.T., Lipkin W.I. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from Southern Africa. PLoS Pathog. 2009, 5:e1000455.
22. Brindley M.A., Hunt C.L., Kondratowicz A.S., Bowman J., Sinn P.L., McCray P.B., Quinn K., Weller M.L., Chiorini J.A., Maury W. Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein. Virology 2011, 415:83-94.
23. Brooks D.G., Trifilo M.J., Edelmann K.H., Teyton L., McGavern D.B., Oldstone M.B.A. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 2006, 12:1301-1309.
24. Brunotte L., Lelke M., Hass M., Kleinsteuber K., Becker-Ziaja B., Günther S. Domain structure of Lassa virus L protein. J. Virol. 2011, 85:324-333.
25. Burri D.J., Pasqual G., Rochat C., Seidah N.G., Pasquato A., Kunz S. Molecular characterization of the processing of arenavirus envelope glycoprotein precursors by subtilisin kexin Isozyme-1/site-1 protease. J. Virol. 2012, 86:4935-4946.
26. Cao W., Henry M., Borrow P., Yamada H., Elder J., Ravkov E., Nichol S., Compans R., Campbell K., Oldstone M. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 1998, 282:2079-2081.
27. Capul A.A., Perez M., Burke E., Kunz S., Buchmeier M.J., de la Torre J.C. Arenavirus Z-glycoprotein association requires Z myristoylation but not functional ring or late domains. J. Virol. 2007, 81:9451-9460.
28. Casabona J.C., Levingston Macleod J.M., Loureiro M.E., Gomez G.A., Lopez N. The RING domain and the L79 residue of Z protein are involved in both the rescue of nucleocapsids and the incorporation of glycoproteins into infectious chimeric arenavirus-like particles. J. Virol. 2009, 83:7029-7039.
29. Cashman K.A., Smith M.A., Twenhafel N.A., Larson R.A., Jones K.F., Allen Iii R.D., Dai D., Chinsangaram J., Bolken T.C., Hruby D.E., Amberg S.M., Hensley L.E., Guttieri M.C. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res. 2011, 90:70-79.
30. Brief report: lymphocytic choriomeningitis virus transmitted through solid organ transplantation - Massachussetts, 2008. Morb. Mortal. Wkly. Rep. 2008, 57:799-801. Centers for Disease Control and Prevention.
31. Charrel R.N., Lamballerie X.d. Arenaviruses other than Lassa virus. Antiviral Res. 2003, 57:89-100.
32. Choe H., Jemielity S., Abraham J., Radoshitzky S.R., Farzan M. Transferrin receptor 1 in the zoonosis and pathogenesis of New World hemorrhagic fever arenaviruses. Curr. Opin. Microbiol. 2011, 14:476-482.
33. Cordo S.M., Candurra N.A., Damonte E.B. Myristic acid analogs are inhibitors of Junin virus replication. Microbes Infect. 1999, 1:609-614.
34. Cornu T.I., de la Torre J.C. RING finger Z protein of Lymphocytic Choriomeningitis Virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome. J. Virol. 2001, 75:9415-9426.
35. Cummins D., McCormick J.B., Bennett D., et al. Acute sensorineural deafness in Lassa fever. JAMA 1990, 264:2093-2096.
36. Delgado S., Erickson B.R., Agudo R., Blair P.J., Vallejo E., Albariño C.G., Vargas J., Comer J.A., Rollin P.E., Ksiazek T.G., Olson J.G., Nichol S.T. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog. 2008, 4:e1000047.
37. Droniou-Bonzom M.E., Reignier T., Oldenburg J.E., Cox A.U., Exline C.M., Rathbun J.Y., Cannon P.M. Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP. J. Virol. 2011, 85:13457-13462.
38. Eichler R., Lenz O., Garten W., Strecker T. The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP-C. Virol. J. 2006, 3:41.
39. Eichler R., Lenz O., Strecker T., Eickmann M., Klenk H.-D., Garten W. Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. EMBO Rep. 2003, 4:1084-1088.
40. Eichler R., Lenz O., Strecker T., Garten W. Signal peptide of Lassa virus glycoprotein GP-C exhibits an unusual length. FEBS Lett. 2003, 538:203-206.
41. Enria D.A., Briggiler A.M., Sánchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 2008, 78:132-139.
42. Eschli B., Quirin K., Wepf A., Weber J., Zinkernagel R., Hengartner H. Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins. J. Virol. 2006, 80:5897-5907.
43. Fan L., Briese T., Lipkin W.I. Z proteins of New World arenaviruses bind RIG-I and interfere with Type I interferon induction. J. Virol. 2010, 84:1785-1791.
44. Ferron F., Decroly E., Selisko B., Canard B. The viral RNA capping machinery as a target for antiviral drugs. Antiviral Res. 2012, 96:21-31.
45. Fischer S.A., Graham M.B., Kuehnert M.J., Kotton C.N., Srinivasan A., Marty F.M., Comer J.A., Guarner J., Paddock C.D., DeMeo D.L., Shieh W.-J., Erickson B.R., Bandy U., DeMaria A., Davis J.P., Delmonico F.L., Pavlin B., Likos A., Vincent M.J., Sealy T.K., Goldsmith C.S., Jernigan D.B., Rollin P.E., Packard M.M., Patel M., Rowland C., Helfand R.F., Nichol S.T., Fishman J.A., Ksiazek T., Zaki S.R. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 2006, 354:2235-2249.
46. Fisher-Hoch S.P., Hutwagner L., Brown B., McCormick J.B. Effective vaccine for Lassa fever. J. Virol. 2000, 74:6777-6783.
47. Flanagan M.L., Oldenburg J., Reignier T., Holt N., Hamilton G.A., Martin V.K., Cannon P.M. New World Clade B arenaviruses can use Transferrin Receptor 1 (TfR1)-dependent and -independent entry pathways, and glycoproteins from human pathogenic strains are associated with the use of TfR1. J. Virol. 2008, 82:938-948.
48. Fulhorst C.F., Cajimat M.N.B., Milazzo M.L., Paredes H., de Manzione N.M.C., Salas R.A., Rollin P.E., Ksiazek T.G. Genetic diversity between and within the arenavirus species indigenous to western Venezuela. Virology 2008, 378:205-213.
49. Furuta Y., Takahashi K., Shiraki K., Sakamoto K., Smee D.F., Barnard D.L., Gowen B.B., Julander J.G., Morrey J.D. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009, 82:95-102.
50. García C.C., Djavani M., Topisirovic I., Borden K.L.B., Salvato M.S., Damonte E.B. Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds. J. Gen. Virol. 2006, 87:1217-1228.
51. García C.C., Topisirovic I., Djavani M., Borden K.L.B., Damonte E.B., Salvato M.S. An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein. Biochem. Biophys. Res. Commun. 2010, 393:625-630.
52. Gramberg T., Hofmann H., Möller P., Lalor P.F., Marzi A., Geier M., Krumbiegel M., Winkler T., Kirchhoff F., Adams D.H., Becker S., Münch J., Pöhlmann S. LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology 2005, 340:224-236.
53. Groseth A., Hoenen T., Weber M., Wolff S., Herwig A., Kaufmann A., Becker S. Tacaribe virus but not junin virus infection induces cytokine release from primary human monocytes and macrophages. PLoS. Negl. Trop. Dis. 2011, 5:e1137.
54. Groseth A., Wolff S., Strecker T., Hoenen T., Becker S. Efficient budding of the Tacaribe virus matrix protein Z requires the nucleoprotein. J. Virol. 2010, 84:3603-3611.
55. Günther S., Lenz O. Lassa virus. Crit. Rev. Clin. Lab. Sci. 2004, 41:339-390.
56. Harrison L.H., Halsey N.A., McKee K.T., Peters C.J., Barrera Oro J.G., Briggiler A.M., Feuillade M.R., Maiztegui J.I. Clinical case definitions for argentine hemorrhagic fever. Clin. Infect. Dis. 1999, 28:1091-1094.
57. Hass M., Lelke M., Busch C., Becker-Ziaja B., Günther S. Mutational evidence for a structural model of the Lassa virus RNA polymerase domain and identification of two residues, Gly1394 and Asp1395, that are critical for transcription but not replication of the genome. J. Virol. 2008, 82:10207-10217.
58. Hastie K.M., Kimberlin C.R., Zandonatti M.A., MacRae I.J., Saphire E.O. Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression. Proc. Natl. Acad. Sci. 2011, 108:2396-2401.
59. Heller M.V., Saavedra M.C., Falcoff R., Maiztegui J.I., Molinas F.C. Increased tumor necrosis factor-α levels in argentine hemorrhagic fever. J. Infect. Dis. 1992, 166:1203-1204.
60. Huang C., Kolokoltsova O.A., Yun N.E., Seregin A.V., Poussard A.L., Walker A.G., Brasier A.R., Zhao Y., Tian B., de la Torre J.C., Paessler S. Junín virus infection activates the Type I interferon pathway in a RIG-I-dependent manner. PLoS. Negl. Trop. Dis. 2012, 6:e1659.
61. Imperiali M., Spörri R., Hewitt J., Oxenius A. Post-translational modification of α-dystroglycan is not critical for lymphocytic choriomeningitis virus receptor function in vivo. J. Gen. Virol. 2008, 89:2713-2722.
62. Inamori K.-I., Yoshida-Moriguchi T., Hara Y., Anderson M.E., Yu L., Campbell K.P. Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science 2012, 335:93-96.
63. Jácamo R., López N., Wilda M., Franze-Fernández M.T. Tacaribe virus Z protein interacts with the L polymerase protein to inhibit viral RNA synthesis. J. Virol. 2003, 77:10383-10393.
64. Jahrling P.B., Hesse R.A., Rhoderick J.B., Elwell M.A., Moe J.B. Pathogenesis of a Pichinde virus strain adapted to produce lethal infections in guinea pigs. Infect. Immun. 1981, 32:872-880.
65. Johnson K.M., McCormick J.B., Webb P.A., Smith E.S., Elliott L.H., King I.J. Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 1987, 155:456-464.
66. Kentsis A., Dwyer E.C., Perez J.M., Sharma M., Chen A., Pan Z.Q., Borden K.L.B. The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E. J. Mol. Biol. 2001, 312:609-623.
67. Kentsis A., Gordon R.E., Borden K.L.B. Self-assembly properties of a model RING domain. Proc. Natl. Acad. Sci. 2002, 99:667-672.
68. Kerber R., Rieger T., Busch C., Flatz L., Pinschewer D.D., Kümmerer B.M., Günther S. Cross-species analysis of the replication complex of old world arenaviruses reveals two nucleoprotein sites involved in L protein function. J. Virol. 2011, 85:12518-12528.
69. Kranzusch P.J., Whelan S.P.J. Arenavirus Z protein controls viral RNA synthesis by locking a polymerase-promoter complex. Proc. Natl. Acad. Sci. 2011, 108:19743-19748.
70. Kumar N., Wang J., Lan S., Danzy S., McLay Schelde L., Seladi-Schulman J., Ly H., Liang Y. Characterization of virulence-associated determinants in the envelope glycoprotein of Pichinde virus. Virology 2012, 433:97-103.
71. Kunz S., Rojek J.M., Kanagawa M., Spiropoulou C.F., Barresi R., Campbell K.P., Oldstone M.B.A. Posttranslational modification of α-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE Is critical for virus binding. J. Virol. 2005, 79:14282-14296.
72. Kunz S., Sevilla N., McGavern D.B., Campbell K.P., Oldstone M.B.A. Molecular analysis of the interaction of LCMV with its cellular receptor α-dystroglycan. J. Cell Biol. 2001, 155:301-310.
73. Lee A.M., Rojek J.M., Gundersen A., Ströher U., Juteau J.-M., Vaillant A., Kunz S. Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. Virology 2008, 372:107-117.
74. Lee A.M., Rojek J.M., Spiropoulou C.F., Gundersen A.T., Jin W., Shaginian A., York J., Nunberg J.H., Boger D.L., Oldstone M.B.A., Kunz S. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J. Biol. Chem. 2008, 283:18734-18742.
75. Lee K.J., Novella I.S., Teng M.N., Oldstone M.B.A., de la Torre J.C. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J. Virol. 2000, 74:3470-3477.
76. Lenz O., ter Meulen J., Klenk H.-D., Seidah N.G., Garten W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl. Acad. Sci. 2001, 98:12701-12705.
77. Levingston Macleod J.M., D'Antuono A., Loureiro M.E., Casabona J.C., Gomez G.A., Lopez N. Identification of two functional domains within the arenavirus nucleoprotein. J. Virol. 2011, 85:2012-2023.
78. Levis S.C., Saavedra M.C., Ceccoli C., Feuillade M.R., Enria D.A., Maiztequi J.I., Falcoff R. Correlation between endogenous interferon and the clinical evolution of patients with Argentine hemorrhagic fever. J. Interferon Res. 1985, 5:383-389.
79. Lisieux T., Coimbra M., Nassar E.S., Burattini M.N., Souza L.T.M.d., Ferreira I.B., Rocco I.M., Rosa A.P.A.T.d., Vasconcelos P.F.C., Pinheiro F.P., LeDuc J.W., Rico-Hesse R., Gonzalez J.-P., Jahrling P.B., Tesh R.B. New arenavirus isolated in Brazil. Lancet 1994, 343:391-392.
80. López N., Jácamo R., Franze-Fernández M.a.T. Transcription and RNA replication of Tacaribe virus genome and antigenome analogs require N and L proteins: Z protein is an inhibitor of these processes. J. Virol. 2001, 75:12241-12251.
81. Loureiro M.E., D'Antuono A., Levingston Macleod J.M., López N. Uncovering viral protein-protein interactions and their role in arenavirus life cycle. Viruses 2012, 4:1651-1667.
82. Loureiro M.E., Wilda M., Levingston Macleod J.M., D'Antuono A., Foscaldi S., Buslje C.M., Lopez N. Molecular determinants of arenavirus Z protein homo-oligomerization and L polymerase binding. J. Virol. 2011, 85:12304-12314.
83. MacNeil A., Stroher U., Farnon E., Campbell S., Cannon D., Paddock C.D., Drew C.P., Kuehnert M., Knust B., Gruenenfelder R., Zaki S.R., Rollin P.E., Nichol S.T., team L.T.I. Solid organ transplant-associated lymphocytic choriomeningitis, United States, 2011. Emerging Infect. Dis. 2012, 18:1256-1262.
84. 1-antitrypsin variants. PLoS. Negl. Trop. Dis. 2009, 3:e446.
85. Maiztegui J.I., McKee K.T., Oro J.G.B., Harrison L.H., Gibbs P.H., Feuillade M.R., Enria D.A., Briggiler A.M., Levis S.C., Ambrosio A.M., Halsey N.A., Peters C.J. Protective efficacy of a live attenuated vaccine against argentine hemorrhagic fever. J. Infect. Dis. 1998, 177:277-283. AHF Study Group.
86. Manzione N.d., Salas R.A., Paredes H., Godoy O., Rojas L., Araoz F., Fulhorst C.F., Ksiazek T.G., Mills J.N., Ellis B.A., Peters C.J., Tesh R.B. Venezuelan hemorrhagic fever: clinical and epidemiological studies of 165 cases. Clin. Infect. Dis. 1998, 26:308-313.
87. Marta R.F., Montero V.S., Hack C.E., Sturk A., Maiztegui J.I., Molinas F.C. Proinflammatory cytokines and elastase-alpha-1-antitrypsin in Argentine hemorrhagic fever. Am. J. Trop. Med. Hyg. 1999, 60:85-89.
88. Martínez-Sobrido L., Giannakas P., Cubitt B., García-Sastre A., de la Torre J.C. Differential inhibition of Type I interferon induction by arenavirus nucleoproteins. J. Virol. 2007, 81:12696-12703.
89. Matloubian M., Kolhekar S.R., Somasundaram T., Ahmed R. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus. J. Virol. 1993, 67:7340-7349.
90. McCormick J.B. Lassa fever. Emergence and Control of Rodent-borne Viral Diseases 1999, 177-195. Elsevier. J.F. Saluzzo, B. Dodet (Eds.).
91. Mendenhall M., Russell A., Juelich T., Messina E.L., Smee D.F., Freiberg A.N., Holbrook M.R., Furuta Y., Torre J.d.l., Nunberg J.H., Gowen B. T-705 (Favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob. Agents Chemother. 2011, 55:782-787.
92. Mendenhall M., Russell A., Smee D.F., Hall J.O., Skirpstunas R., Furuta Y., Gowen B.B. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLoS. Negl. Trop. Dis. 2011, 5:e1342.
93. Messina E.L., York J., Nunberg J.H. Dissection of the role of the stable signal peptide of the arenavirus envelope glycoprotein in membrane fusion. J. Virol. 2012, 86:6138-6145.
94. Moraz M.-L., Kunz S. Pathogenesis of arenavirus hemorrhagic fevers. Expert Rev. Anti Infect. Ther. 2010, 9:49-59.
95. Moreno H., Gallego I., Sevilla N., de la Torre J.C., Domingo E., Martín V. Ribavirin can be mutagenic for arenaviruses. J. Virol. 2011, 85:7246-7255.
96. Morin B., Coutard B., Lelke M., Ferron F., Kerber R., Jamal S., Frangeul A., Baronti C., Charrel R., de Lamballerie X., Vonrhein C., Lescar J., Bricogne G., Günther S., Canard B. The N-terminal domain of the arenavirus L protein is an rna endonuclease essential in mRNA transcription. PLoS Pathog. 2010, 6:e1001038.
97. Neuman B., Bederka L., Stein D., Ting J., Moulton H., Buchmeier M. Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors. Antimicrob. Agents Chemother. 2011, 55:4631-4638.
98. Ortiz-Riaño E., Cheng B.Y.H., de la Torre J.C., Martínez-Sobrido L. The C-terminal region of lymphocytic choriomeningitis virus nucleoprotein contains distinct and segregable functional domains involved in NP-Z interaction and counteraction of the Type I interferon response. J. Virol. 2011, 85:13038-13048.
99. Pannetier D., Faure C., Georges-Courbot M.-C., Deubel V., Baize S. Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to mopeia virus infection. J. Virol. 2004, 78:10516-10524.
100. Pannetier D., Reynard S., Russier M., Journeaux A., Tordo N., Deubel V., Baize S. Human dendritic cells infected with the nonpathogenic mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J. Virol. 2011, 85:8293-8306.
101. Pasqual G., Rojek J.M., Masin M., Chatton J.-Y., Kunz S. Old World arenaviruses enter the host cell via the multivesicular body and depend on the endosomal sorting complex required for transport. PLoS Pathog. 2011, 7:e1002232.
102. Pasquato A., Rochat C., Burri D.J., Pasqual G., la Torre J.C.d., Kunz S. Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. Virology 2012, 423:14-22.
103. Paweska J.T., Sewlall N.H., Ksiazek T.G., Blumberg L.H., Hale M.J., Lipkin W.I., Weyer J., Nichol S.T., Rollin P.E., McMullan L.K., Paddock C.D., Briese T., Mnyaluza J., Dinh T.-H., Mukonka V., Ching P., Duse A., Richards G., Jong G.d., Cohen C., Ikalafeng B., Mugero C., Asomugha C., Malotle M.M., Nteo D.M., Misiani E., Swanepoel R., Zaki S.R. Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerging Infect. Dis. 2009, 15:1598-1602. Outbreak Control and Investigation Teams.
104. Perez M., Craven R.C., de la Torre J.C. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl. Acad. Sci. 2003, 100:12978-12983.
105. Perez M., de la Torre J.C. Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 2003, 77:1184-1194.
106. Peters C.J. Lymphocytic choriomeningitis virus - an old enemy up to new tricks. N. Engl. J. Med. 2006, 354:2208-2211.
107. Pfau C.J. Arenaviruses. Medical Microbiology 1996, The University of Texas Medical Branch at Galveston, Galveston, TX. S. Baron (Ed.).
108. Pinschewer D.D., Perez M., de la Torre J.C. Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation. J. Virol. 2005, 79:4519-4526.
109. Plotch S.J., Bouloy M., Ulmanen I., Krug R.M. A unique cap(m7G pppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell 1981, 23:847-858.
110. Pythoud C., Rodrigo W.W.S.I., Pasqual G., Rothenberger S., Martínez-Sobrido L., de la Torre J.C., Kunz S. Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKKε. J. Virol. 2012, 86:7728-7738.
111. Qi X., Lan S., Wang W., Schelde L.M., Dong H., Wallat G.D., Ly H., Liang Y., Dong C. Cap binding and immune evasion revealed by Lassa nucleoprotein structure. Nature 2010, 468:779-783.
112. Radoshitzky S.R., Abraham J., Spiropoulou C.F., Kuhn J.H., Nguyen D., Li W., Nagel J., Schmidt P.J., Nunberg J.H., Andrews N.C., Farzan M., Choe H. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 2007, 446:92-96.
113. Raju R., Raju L., Hacker D., Garcin D., Compans R., Kolakofsky D. Nontemplated bases at the 5' ends of Tacaribe virus mRNAs. Virology 1990, 74:53-59.
114. Reignier T., Oldenburg J., Flanagan M.L., Hamilton G.A., Martin V.K., Cannon P.M. Receptor use by the Whitewater Arroyo virus glycoprotein. Virology 2008, 371:439-446.
115. Rodrigo W.W.S.I., Ortiz-Riaño E., Pythoud C., Kunz S., de la Torre J.C., Martínez-Sobrido L. Arenavirus nucleoproteins prevent activation of nuclear factor kappa B. J. Virol. 2012, 86:8185-8197.
116. Rojek J.M., Campbell K.P., Oldstone M.B.A., Kunz S. Old World arenavirus infection interferes with the expression of functional α-dystroglycan in the host cell. Mol. Biol. Cell 2007, 18:4493-4507.
117. Rojek J.M., Moraz M.-L., Pythoud C., Rothenberger S., Van der Goot F.G., Campbell K.P., Kunz S. Binding of Lassa virus perturbs extracellular matrix-induced signal transduction via dystroglycan. Cell. Microbiol. 2012, 14:1122-1134.
118. Rojek J.M., Pasqual G., Sanchez A.B., Nguyen N.-T., de la Torre J.-C., Kunz S. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J. Virol. 2010, 84:573-584.
119. Rojek J.M., Spiropoulou C.F., Campbell K.P., Kunz S. Old World and Clade C New World arenaviruses mimic the molecular mechanism of receptor recognition used by α-dystroglycan's host-derived ligands. J. Virol. 2007, 81:5685-5695.
120. Rousseau M.C., Saron M.F., Brouqui P., Bourgeade A. Lymphocytic choriomeningitis virus in southern France. Four case reports and a review of the literature. Eur. J. Epidemiol. 1997, 13:817-823.
121. Sabeti P.C., Varilly P., Fry B., Lohmueller J., Hostetter E., Cotsapas C., Xie X., Byrne E.H., McCarroll S.A., Gaudet R., Schaffner S.F., Lander E.S. Genome-wide detection and characterization of positive selection in human populations. Nature 2007, 449:913-918.
122. Salomoni P., Dvorkina M., Michod D. Role of the promyelocytic leukaemia protein in cell death regulation. Cell Death Dis. 2012, 3:e247.
123. Saunders A.A., Ting J.P.C., Meisner J., Neuman B.W., Perez M., de la Torre J.C., Buchmeier M.J. Mapping the landscape of the lymphocytic choriomeningitis virus stable signal peptide reveals novel functional domains. J. Virol. 2007, 81:5649-5657.
124. Sepúlveda C.S., García C.C., Damonte E.B. Inhibition of arenavirus infection by thiuram and aromatic disulfides. Antiviral Res. 2010, 87:329-337.
125. Sepúlveda C.S., García C.C., Fascio M.L., D'Accorso N.B., Docampo Palacios M.L., Pellón R.F., Damonte E.B. Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative. Antiviral Res. 2012, 93:16-22.
126. Sevilla N., Kunz S., Holz A., Lewicki H., Homann D., Yamada H., Campbell K.P., de la Torre J.C., Oldstone M.B.A. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J. Exp. Med. 2000, 192:1249-1260.
127. Sevilla N., McGavern D.B., Teng C., Kunz S., Oldstone M.B.A. Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion. J. Clin. Invest. 2004, 113:737-745.
128. Shimojima M., Ströher U., Ebihara H., Feldmann H., Kawaoka Y. Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J. Virol. 2012, 86:2067-2078.
129. Shtanko O., Imai M., Goto H., Lukashevich I.S., Neumann G., Watanabe T., Kawaoka Y. A role for the C terminus of Mopeia virus nucleoprotein in its incorporation into Z protein-induced virus-like particles. J. Virol. 2010, 84:5415-5422.
130. Shtanko O., Watanabe S., Jasenosky L.D., Watanabe T., Kawaoka Y. ALIX/AIP1 is required for NP incorporation into Mopeia virus Z-induced virus-like particles. J. Virol. 2011, 85:3631-3641.
131. Smelt S.C., Borrow P., Kunz S., Cao W., Tishon A., Lewicki H., Campbell K.P., Oldstone M.B.A. Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor α-dystroglycan correlate with viral tropism and disease kinetics. J. Virol. 2001, 75:448-457.
132. Spiropoulou C.F., Kunz S., Rollin P.E., Campbell K.P., Oldstone M.B.A. New World arenavirus Clade C, but not Clade A and B viruses, utilizes α-dystroglycan as its major receptor. J. Virol. 2002, 76:5140-5146.
133. Strecker T., Eichler R., Meulen J.t., Weissenhorn W., Dieter Klenk H., Garten W., Lenz O. Lassa virus Z protein is a matrix protein sufficient for the release of virus-like particles. J. Virol. 2003, 77:10700-10705.
134. Strecker T., Maisa A., Daffis S., Eichler R., Lenz O., Garten W. The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. Virol. J. 2006, 3:93.
135. Sullivan B.M., Emonet S.F., Welch M.J., Lee A.M., Campbell K.P., de la Torre J.C., Oldstone M.B. Point mutation in the glycoprotein of lymphocytic choriomeningitis virus is necessary for receptor binding, dendritic cell infection, and long-term persistence. Proc. Natl. Acad. Sci. 2011, 108:2969-2974.
136. Urata S., Yun N., Pasquato A., Paessler S., Kunz S., de la Torre J.C. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J. Virol. 2011, 85:795-803.
137. Vieth S., Torda A.E., Asper M., Schmitz H., Günther S. Sequence analysis of L RNA of Lassa virus. Virology 2004, 318:153-168.
138. Volpon L., Osborne M.J., Capul A.A., de la Torre J.C., Borden K.L.B. Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E. Proc. Natl. Acad. Sci. 2010, 107:5441-5446.
139. Walker D., McCormick J., Johnson K., Webb P., Komba-Kono G., Elliott L., Gardner J. Pathologic and virologic study of fatal Lassa fever in man. Am. J. Pathol. 1982, 107:349-356.
140. Wilda M., Lopez N., Casabona J.C., Franze-Fernandez M.T. Mapping of the Tacaribe arenavirus Z-protein binding sites on the L protein identified both amino acids within the putative polymerase domain and a region at the N terminus of L that are critically involved in binding. J. Virol. 2008, 82:11454-11460.
141. Wright K.E., Spiro R.C., Burns J.W., Buchmeier M.J. Post-translational processing of the glycoproteins of lymphocytic choriomeningitis virus. Virology 1990, 177:175-183.
142. Wright R., Johnson D., Neumann M., Ksiazek T.G., Rollin P., Keech R.V., Bonthius D.J., Hitchon P., Grose C.F., Bell W.E., Bale J.F. Congenital lymphocytic choriomeningitis virus syndrome: a disease that mimics congenital toxoplasmosis or cytomegalovirus infection. Pediatrics 1997, 100:e9.
143. Yamamoto T., Kato Y., Karita M., Kawaguchi M., Shibata N., Kobayashi M. Expression of genes related to muscular dystrophy with lissencephaly. Pediatr. Neurol. 2004, 31:183-190.
144. York J., Dai D., Amberg S.M., Nunberg J.H. PH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J. Virol. 2008, 82:10932-10939.
145. York J., Nunberg J.H. Distinct requirements for signal peptidase processing and function in the stable signal peptide subunit of the Junín virus envelope glycoprotein. Virology 2007, 359:72-81.
146. Zhou S., Cerny A.M., Zacharia A., Fitzgerald K.A., Kurt-Jones E.A., Finberg R.W. Induction and inhibition of Type I interferon responses by distinct components of lymphocytic choriomeningitis virus. J. Virol. 2010, 84:9452-9462.